South Korea antirheumatic drug market was valued at US$663.833 million in 2019. Since this age group is increasingly inclined to getting rheumatoid joint pain, and regardless of whether somebody contracts infection at an early age, side effects of rheumatoid arthritis begin showing up for the most part during this age. In this manner, the rising geriatric populace in South Korea will keep on driving with it the instances of rheumatoid arthritis, accordingly boosting south korea antirheumatic drugs market development of antirheumatic drugs.